Product
Interferon beta type 1a
Aliases
Avonex
1 clinical trial
2 indications
Indication
Multiple SclerosisIndication
Relapsing-RemittingClinical trial
An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label ExtensionStatus: Recruiting, Estimated PCD: 2029-11-05